204 related articles for article (PubMed ID: 35301709)
1. Checkpoint CD47 expression in classical Hodgkin lymphoma.
Gholiha AR; Hollander P; Löf L; Glimelius I; Hedstrom G; Molin D; Hjalgrim H; Smedby KE; Hashemi J; Amini RM; Enblad G
Br J Haematol; 2022 Jun; 197(5):580-589. PubMed ID: 35301709
[TBL] [Abstract][Full Text] [Related]
2. Expression of CD47 antigen in Reed-Sternberg cells as a new potential biomarker for classical Hodgkin lymphoma.
López-Pereira B; Fernández-Velasco AA; Fernández-Vega I; Corte-Torres D; Quirós C; Villegas JA; Palomo P; González S; González AP; Payer Á; Bernal T; Moro-García MA; Alonso-Arias R; Alonso-Álvarez S; Colado E
Clin Transl Oncol; 2020 May; 22(5):782-785. PubMed ID: 31359339
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
Sakakibara A; Kohno K; Eladl AE; Klaisuwan T; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Kato S; Asano N; Nakamura S; Satou A
Histopathology; 2018 Jun; 72(7):1156-1163. PubMed ID: 29380399
[TBL] [Abstract][Full Text] [Related]
4. Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma.
Gholiha AR; Hollander P; Glimelius I; Hedstrom G; Molin D; Hjalgrim H; Smedby KE; Hashemi J; Amini RM; Enblad G
Blood Adv; 2021 Mar; 5(6):1671-1681. PubMed ID: 33720338
[TBL] [Abstract][Full Text] [Related]
5. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M
BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Utility of STAT6 and pSTAT6 Immunohistochemistry for Distinguishing Classic Hodgkin Lymphoma and Peripheral T-Cell Lymphoma With Hodgkin and Reed-Sternberg-like Cells.
Satou A; Takahara T; Yamashita D; Seki M; Kato S; Tanioka F; Tsuyuki T; Wada E; Sakurai K; Karube K; Tsuzuki T; Nakamura S
Am J Surg Pathol; 2023 Aug; 47(8):897-906. PubMed ID: 37248961
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 and EBV LMP1 expressions in classic Hodgkin lymphomas and its correlation with clinicopathological parameters and prognosis.
Özdemir S; Ton Ö; Kabukcuoğlu F
Turk J Med Sci; 2022 Aug; 52(4):1013-1021. PubMed ID: 36326378
[TBL] [Abstract][Full Text] [Related]
8. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.
Carey CD; Gusenleitner D; Lipschitz M; Roemer MGM; Stack EC; Gjini E; Hu X; Redd R; Freeman GJ; Neuberg D; Hodi FS; Liu XS; Shipp MA; Rodig SJ
Blood; 2017 Nov; 130(22):2420-2430. PubMed ID: 28893733
[TBL] [Abstract][Full Text] [Related]
9. The Prognostic Value of Eight Immunohistochemical Markers Expressed in the Tumor Microenvironment and on Hodgkin Reed-Sternberg Cells in Pediatric Patients With Classical Hodgkin Lymphoma.
Zijtregtop EAM; Tromp I; Dandis R; Zwaan CM; Lam KH; Meyer-Wentrup FAG; Beishuizen A
Pathol Oncol Res; 2022; 28():1610482. PubMed ID: 36032657
[TBL] [Abstract][Full Text] [Related]
10. The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative.
Patel SS; Weirather JL; Lipschitz M; Lako A; Chen PH; Griffin GK; Armand P; Shipp MA; Rodig SJ
Blood; 2019 Dec; 134(23):2059-2069. PubMed ID: 31697809
[TBL] [Abstract][Full Text] [Related]
11. Expression and Prognostic Significance of CD47-SIRPA Macrophage Checkpoint Molecules in Colorectal Cancer.
Sugimura-Nagata A; Koshino A; Inoue S; Matsuo-Nagano A; Komura M; Riku M; Ito H; Inoko A; Murakami H; Ebi M; Ogasawara N; Tsuzuki T; Takahashi S; Kasugai K; Kasai K; Inaguma S
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33799989
[TBL] [Abstract][Full Text] [Related]
12. PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma.
Kawashima M; Carreras J; Higuchi H; Kotaki R; Hoshina T; Okuyama K; Suzuki N; Kakizaki M; Miyatake Y; Ando K; Nakayama M; Umezu S; Horie R; Higuchi Y; Katagiri K; Goyama S; Kitamura T; Chamoto K; Yano S; Nakamura N; Kotani A
Leukemia; 2020 Sep; 34(9):2405-2417. PubMed ID: 32089543
[TBL] [Abstract][Full Text] [Related]
13. Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma.
Aoki T; Chong LC; Takata K; Milne K; Marshall A; Chavez EA; Miyata-Takata T; Ben-Neriah S; Unrau D; Telenius A; Boyle M; Weng AP; Savage KJ; Scott DW; Farinha P; Shah SP; Nelson BH; Steidl C
Proc Natl Acad Sci U S A; 2021 Oct; 118(41):. PubMed ID: 34615710
[TBL] [Abstract][Full Text] [Related]
14. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman J; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Ansell S; Kato K; Farsaci B; Sumbul A; Armand P; Neuberg DS; Pinkus GS; Ligon AH; Rodig SJ; Shipp MA
J Clin Oncol; 2018 Apr; 36(10):942-950. PubMed ID: 29394125
[TBL] [Abstract][Full Text] [Related]
15. Increased STAT expression in Reed-Sternberg cells as a potential positive prognostication biomarker in Hodgkin lymphoma.
Zargari A; Cummins KD; Hosking P; Pham A; Hawkes E; Ting SB
Pathology; 2023 Aug; 55(5):650-655. PubMed ID: 37169648
[TBL] [Abstract][Full Text] [Related]
16. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.
Liu WR; Shipp MA
Blood; 2017 Nov; 130(21):2265-2270. PubMed ID: 29167175
[TBL] [Abstract][Full Text] [Related]
17. Aberrant T-cell antigen expression in classical Hodgkin lymphoma is associated with decreased event-free survival and overall survival.
Venkataraman G; Song JY; Tzankov A; Dirnhofer S; Heinze G; Kohl M; Traverse-Glehen A; Eberle FC; Hanson JC; Raffeld MA; Pittaluga S; Jaffe ES
Blood; 2013 Mar; 121(10):1795-804. PubMed ID: 23305738
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy.
Yang Z; Xu J; Li R; Gao Y; He J
J Cancer Res Clin Oncol; 2019 Dec; 145(12):3055-3065. PubMed ID: 31522278
[TBL] [Abstract][Full Text] [Related]
19. Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.
Roemer MG; Advani RH; Redd RA; Pinkus GS; Natkunam Y; Ligon AH; Connelly CF; Pak CJ; Carey CD; Daadi SE; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Shipp MA; Rodig SJ
Cancer Immunol Res; 2016 Nov; 4(11):910-916. PubMed ID: 27737878
[TBL] [Abstract][Full Text] [Related]
20. High proportions of PD-1
Hollander P; Kamper P; Smedby KE; Enblad G; Ludvigsen M; Mortensen J; Amini RM; Hamilton-Dutoit S; d'Amore F; Molin D; Glimelius I
Blood Adv; 2017 Aug; 1(18):1427-1439. PubMed ID: 29296784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
